| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Kevin C J Yuen, David B Dunge. Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 16 Suppl A. 2006-12-07. PMID:16624605. |
paradoxically, adults with gh deficiency and patients with acromegaly are both predisposed to glucose intolerance and insulin resistance; however, one cannot extrapolate from these pathological conditions to determine the true metabolic roles of gh and igf-i in glucose homeostasis. |
2006-12-07 |
2023-08-12 |
human |
| Martin Horan, Vicky Newsway, Yasmin, Mark D Lewis, Tammy E Easter, D Aled Rees, Arti Mahto, David S Millar, Annie M Procter, Maurice F Scanlon, Ian B Wilkinson, Ian P Hall, Amanda Wheatley, John Blakey, Philip M W Bath, John R Cockcroft, Michael Krawczak, David N Coope. Genetic variation at the growth hormone (GH1) and growth hormone receptor (GHR) loci as a risk factor for hypertension and stroke. Human genetics. vol 119. issue 5. 2006-12-01. PMID:16572267. |
an increased prevalence of both hypertension and cerebrovascular stroke is apparent in growth hormone (gh) deficiency whilst hypertension is a frequent complication in acromegaly. |
2006-12-01 |
2023-08-12 |
human |
| Marek Bolanowski, Beata Kos-Kudła, Marta Rzeszutko, Marek Marciniak, Katarzyna Zatońsk. [Five year remission of GHRH secreting bronchial neuroendocrine tumor with symptoms of acromegaly. Utility of chromogranin A in the monitoring of the disease]. Endokrynologia Polska. vol 57. issue 1. 2006-11-28. PMID:16575760. |
acromegaly is usually caused by excess gh (growth hormone) secretion by pituitary adenoma. |
2006-11-28 |
2023-08-12 |
Not clear |
| Marek Bolanowski, Beata Kos-Kudła, Marta Rzeszutko, Marek Marciniak, Katarzyna Zatońsk. [Five year remission of GHRH secreting bronchial neuroendocrine tumor with symptoms of acromegaly. Utility of chromogranin A in the monitoring of the disease]. Endokrynologia Polska. vol 57. issue 1. 2006-11-28. PMID:16575760. |
the diagnosis of acromegaly in 61-year old woman was based on typical clinical picture and elevated gh and igf-1(insulin-like growth factor-1) levels. |
2006-11-28 |
2023-08-12 |
Not clear |
| Marek Bolanowski, Beata Kos-Kudła, Marta Rzeszutko, Marek Marciniak, Katarzyna Zatońsk. [Five year remission of GHRH secreting bronchial neuroendocrine tumor with symptoms of acromegaly. Utility of chromogranin A in the monitoring of the disease]. Endokrynologia Polska. vol 57. issue 1. 2006-11-28. PMID:16575760. |
the secretion of gh, igf-1 and ghrh were normalized and progression of acromegaly was stopped after the carcinoid tumor surgery. |
2006-11-28 |
2023-08-12 |
Not clear |
| Marek Bolanowski, Beata Kos-Kudła, Marta Rzeszutko, Marek Marciniak, Katarzyna Zatońsk. [Five year remission of GHRH secreting bronchial neuroendocrine tumor with symptoms of acromegaly. Utility of chromogranin A in the monitoring of the disease]. Endokrynologia Polska. vol 57. issue 1. 2006-11-28. PMID:16575760. |
currently, 5 year after surgery, acromegaly is still in the remission, as the normal levels of gh, igf-1, chromogranin a and normal chest and pituitary images confirm. |
2006-11-28 |
2023-08-12 |
Not clear |
| Annamaria Colao, Rosario Pivonello, Luigi M Cavallo, Maria Gaccione, Renata S Auriemma, Felice Esposito, Paolo Cappabianca, Gaetano Lombard. Age changes the diagnostic accuracy of mean profile and nadir growth hormone levels after oral glucose in postoperative patients with acromegaly. Clinical endocrinology. vol 65. issue 2. 2006-11-21. PMID:16886969. |
this analytical, retrospective study was designed to select cut-off thresholds of mean gh levels during a diurnal profile and nadir gh levels after oral glucose tolerance test (ogtt) according to age to diagnose surgical remission of acromegaly. |
2006-11-21 |
2023-08-12 |
Not clear |
| Eva Horvath, Kalman Kovac. Pathology of acromegaly. Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047379. |
gh cell hyperplasia can also be associated with acromegaly in patients with extrapituitary gh-releasing hormone secreting tumors. |
2006-11-21 |
2023-08-12 |
Not clear |
| Eva Horvath, Kalman Kovac. Pathology of acromegaly. Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047379. |
the medical therapy of acromegaly is reviewed briefly, including long-acting somatostatin analogs and pegvisomant, a gh receptor blocker. |
2006-11-21 |
2023-08-12 |
Not clear |
| M Tzanel. Dynamic tests and basal values for defining active acromegaly. Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047383. |
acromegaly is a rare disease caused by excess secretion of growth hormone (gh), usually from a pituitary somatotrope adenoma. |
2006-11-21 |
2023-08-12 |
human |
| M Tzanel. Dynamic tests and basal values for defining active acromegaly. Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047383. |
the increase in morbidity and mortality associated with acromegaly is the result of gh and insulin-like growth factor (igf)-i oversecretion and the direct mass effect of the pituitary tumor. |
2006-11-21 |
2023-08-12 |
human |
| M Tzanel. Dynamic tests and basal values for defining active acromegaly. Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047383. |
the standard method for the diagnosis of acromegaly has been the measuring of gh nadir (ghn) during an oral glucose tolerance test (ogtt) which in normal individuals is undetectable, while acromegalics failed to suppress gh levels. |
2006-11-21 |
2023-08-12 |
human |
| M Tzanel. Dynamic tests and basal values for defining active acromegaly. Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047383. |
determination of igf-i levels is useful as they correlate with clinical features of acromegaly and with the 24-hour mean gh levels. |
2006-11-21 |
2023-08-12 |
human |
| M Tzanel. Dynamic tests and basal values for defining active acromegaly. Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047383. |
according to the more recent consensus, a random gh <0.4 microg/l and igf-i in the age- and gender-matched normal range exclude the diagnosis of acromegaly. |
2006-11-21 |
2023-08-12 |
human |
| A J van der Lely, John J Kopchic. Growth hormone receptor antagonists. Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047392. |
the currently available long-acting somatostatin analogs normalize serum growth hormone (gh) levels and insulin-like growth factor-i levels in approximately 60% of patients with acromegaly. |
2006-11-21 |
2023-08-12 |
human |
| John P Monso. Is there still a role for radiotherapy in acromegaly? Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047393. |
external radiotherapy (ideally 3-field radiotherapy with a daily fractional dose no higher than 1.8 gy or conformal irradiation) has been used extensively in the treatment of acromegaly, and virtually all studies have documented a predictable but slow reduction in growth hormone (gh) excess, which is at its maximum in the first year after treatment (30-50%) and continues at an average rate of 10-15% thereafter in the long term. |
2006-11-21 |
2023-08-12 |
Not clear |
| John P Monso. Is there still a role for radiotherapy in acromegaly? Neuroendocrinology. vol 83. issue 3-4. 2006-11-21. PMID:17047393. |
the development of potent medical therapies for acromegaly (somatostatin analogues and the gh receptor antagonist) has called into question the role of radiotherapy in the treatment of this disease. |
2006-11-21 |
2023-08-12 |
Not clear |
| Ritva Kauppinen-Mäkelin, Timo Sane, Harri Sintonen, Helene Markkanen, Matti J Välimäki, Eliisa Löyttyniemi, Leo Niskanen, Antti Reunanen, Ulf-Håkan Stenma. Quality of life in treated patients with acromegaly. The Journal of clinical endocrinology and metabolism. vol 91. issue 10. 2006-11-13. PMID:16849407. |
it is not known to what extent quality of life of patients treated for acromegaly is dependent on levels of gh and igf-i attained. |
2006-11-13 |
2023-08-12 |
Not clear |
| E Endert, M van Rooden, E Fliers, M F Prummel, W M Wiersing. Establishment of reference values for endocrine tests--part V: acromegaly. The Netherlands journal of medicine. vol 64. issue 7. 2006-10-10. PMID:16929084. |
plasma insulin-like growth factor 1 (igf-1) and the response of growth hormone (gh) to oral glucose are frequently used in the evaluation of patients suspected of acromegaly. |
2006-10-10 |
2023-08-12 |
Not clear |
| David R Clemmon. Clinical utility of measurements of insulin-like growth factor 1. Nature clinical practice. Endocrinology & metabolism. vol 2. issue 8. 2006-09-21. PMID:16932333. |
by contrast, in acromegaly, gh is the predominant determinant of igf-i levels and, therefore, measurement of igf-i is a very useful diagnostic test. |
2006-09-21 |
2023-08-12 |
Not clear |